Fundraising Fox
Delos Capital
Venture capitalCambridge · Seed–Growth · 13 people tracked
Also known as DELOS ADVISORS LIMITED · DELOS ADVISORS, INC. · DELOS WEALTH ADVISORS, LLC
Find your way into Delos Capital
Sign up to see every warm intro you have to Delos Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Delos Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Delos Capital invests in life sciences and biotech companies, seeking extraordinary science and outstanding founding teams focused on treating disease and improving human health. The firm draws on the diverse skills of seasoned entrepreneurs and scientists together with a global network to support ground-breaking medical innovations. It backs visionary companies developing next-generation therapeutics and genetic medicines, aiming for lasting, positive impact on patients worldwide.
Source: firm website, verified Sep 29, 2026.
Team · 13 people
from the firm's website & curated & public directories
What they invest in
from 30 of 40 portfolio companiesBiotech ×23Healthtech ×23Medical Devices ×17Deep Tech ×5AI & Machine Learning ×3Digital Health ×2Hardware ×2Longevity ×2
HQs:United States×25Canada×1Singapore×1
Who they back
founder profiles across 15 portfolio companiesFounding team size:solo founder×92 founders×33 founders×24+ founders×1
Investments · 40 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 42023 · 32021 · 42020 · 12019 · 215 dated
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritEcoR1 CapitalForesite Capital+6 more
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersPivotal Life SciencesQuan CapitalSR One Capital Management+3 more
Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area.
BiotechHealthtechLongevityMedical DevicesSan Diego, US
Qunsheng Ji(Chief Executive Officer)Curt Bradshaw(Chief Scientific Officer)Patrick Yue(Chief Medical Officer)Hailei Lu(Chief Financial Officer)
Co-investorsOrbiMedCreacion Ventures
Tulavi develops medical devices for peripheral nerve surgery, aiming to improve surgical treatment options and patient outcomes in nerve care.
HardwareHealthtechMedical DevicesMountain View, US
Farhad Khosravi(Executive Officer, Director)Fred Khosravi(Chairman & Co-Founder)inJosh Vose(Chief Executive Officer)inCorinne Bright(Executive Officer, Director)
BoardHenry Chen(Director)in
Co-investorsAscension Ventures
Verge Medical (formerly Ostial Corporation) develops medical devices for aorto-ostial vascular interventions, including the FLASH Flex aorto-ostial angioplasty system and the RoVo mechanical thrombectomy device, used by physicians for coronary and peripheral vascular cases.
HealthtechMedical Devices
Mike Buck(Chief Executive Officer)inAdam Tschida(General Manager & COO)in
Co-investorsAmed Ventures
STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients.
BiotechDeep TechHealthtechLongevityMedical Devices
Michael Luther(CEO)in
Co-investorsAscension VenturesBreakout LabsBreakout VenturesNYBC VenturesBoehringer Ingelheim Venture FundKdT Ventures+1 more
Antibiotic developer, maker of cefepime/enmetazobactam (EXBLIFEP).
Co-investorsAndera PartnersBioMedPartnersEMBL VenturesXeraya CapitalForbion
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture PartnersLongitude Capital+9 more
.png)
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonRA CapitalBiotechnology Value FundSoleus Capital
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak Health+8 more
Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients.
BiotechHardwareHealthtechMedical DevicesCampbell, US
Henry Chen(Director)Claudio Argento(Director)Mariam Maghribi(Executive Officer, Director)Amr Salahieh(Director)Casey Gordon(Director)
Co-investorsAmed VenturesThe Capital PartnershipRising TideShangBay Capital LLC
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMedQuan Capital+6 more
Averna Therapeutics is a biotechnology company developing therapeutics.
BiotechDeep TechHealthtechMedical DevicesWatertown, US
Richard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)
BoardRoy Amariglio(Director)Nick Olsen(Director)inStephen Squinto(Director)inMichal Silverberg(Director)in
Co-investorsDeep InsightNovartis Venture FundOrbiMedARC VENTURESInsight Partners
Non-surgical, non-pharmacologic devices to induce weight loss
Co-investorsLongitude CapitalArboretum VenturesHighland Capital PartnersSante Ventures
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)in
Co-investorsBain CapitalAscenta CapitalDigitalis VenturesNew Enterprise Associates (NEA)Bain Capital Life SciencesBain Capital Tech Opportunities+4 more
Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities.
BiotechHealthtechChengdu
Peng Liang(Executive Officer, Director, Promoter)inJoshua Liang(Executive Officer, Director)in
BoardXiaodong Wang(Director)
Woburn, US
LAN BO CHEN(Executive Officer, Director)BRYAN KEANEY(Executive Officer)
BoardHENRY CHEN(Executive Officer, Director)in
Curatia Medical develops and manufactures FDA and CE-approved disposable medical devices for interventional procedures in cardiology, peripheral, neurology, and pulmonology.
Advanced ManufacturingHealthtechMedical DevicesSunnyvale, US
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.
BiotechHealthtechCambridge, US
Jingye Zhou(Founder)inJingye Zhou, Ph.D.(Co-founder & CEO)Jianfeng Xu, Ph.D.(Co-founder & CSO)
Co-investorsNew Alliance Capital
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Co-investors5AM VenturesAju IB InvestmentCatalio Capital Management, LPF-Prime CapitalSolasta VenturesViking Global+10 more
Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.
AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US
Aaron Hurst(Founder)in
Co-investorsEmpire AngelsVoyager CapitalAlly Bridge GroupAmed VenturesAscension VenturesBain Capital Life Sciences+4 more
Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.
HealthtechMedical DevicesCampbell, US
Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in
BoardJames Rogers(Director)Stacy Enxing Seng(Director)
Co-investorsAscension VenturesBain Capital Life SciencesCatalio Capital Management, LPFemHealth VenturesLightstone Ventures
Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.
BiotechHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)inSteven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)in
BoardHenry Chen(Director)inTasneem Dohadwala(Director)in
Co-investorsAngel Physicians FundAscension VenturesCatalyst Health VenturesExcelestar VenturesSparta Group
Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.
HealthtechMedical DevicesWoburn, US
Gregory H. Lambrecht(Director)Carey Hagan(Executive Officer, Director)Cary Hagan(Executive Officer, Director)
BoardRyan Drant(Director)inJeani Delagardelle(Director)Joshua Makower(Director)
Co-investorsNew Enterprise Associates (NEA)Questa CapitalGreenspring AssociatesNew Leaf Venture Partners
Liposeuticals develops proprietary formulations of sterile injectable drugs for hospital use, focusing on anesthesiology, oncology, and infectious disease treatments.
BiotechMedical Devices
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsXeraya CapitalB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesKorea Investment PartnersLumira Ventures+1 more
.jpeg){kind=logo}
Phanes Therapeutics develops oncology and metabolic disease therapeutics targeting cell cycle regulators and related pathways.
BiotechDeep TechHealthtechMedical DevicesSan Diego, US
Dr. Ming Wang(Founder, President and CEO)
Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.
BiotechFemTechHealthtechMedical DevicesBedford, US
Amar Sawhney(Founder)inNICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)
BoardTARA BUTLER(Executive Officer, Director, Promoter)
Co-investorsAscension VenturesCatalyst Health VenturesClavystBioFemHealth VenturesIyengar Capital PartnersSparta Group+1 more
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsVivo CapitalAMR Action FundBoehringer Ingelheim Venture FundKorea Investment PartnersLilly Asia VenturesMatrix Capital Management+1 more
Developer of next-generation insulin solutions
BiotechWaban, US
Richard Berenson(Executive Officer, Director, Promoter)David C. Sweeney(Director)
BoardTim Xiao(Director)inJohn Brooks(Mr. Brooks is the Chairman of the Board of Directors.)
Co-investorsRobin Hood VenturesGreen Park & Golf VenturesJumpstart VenturesSanofi Ventures
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsAvego BioScience CapitalDementia Discovery FundPfizer Venture InvestmentsSV Health InvestorsAgent CapitalPolaris Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AntiosApamaApbioincLuqaOstialRenivaTanvexTruvic
Exits · 2
2 IPOsSyndax PharmaceuticalsNASDAQ: SNDXZenas BiopharmaNASDAQ: ZBIO
Portfolio news
latest coverage across their companiesRejoni · finance.yahoo.com · Jun 16, 2026
Averna Therapeutics · prnewswire.com · Mar 26, 2026
Ensoma · finsmes.com · Sep 23, 2025
Frequently asked questions
- How many investments has Delos Capital made?
- Delos Capital has 40 tracked investments, 2 of which have exited, including 3 dated in the last 24 months.
- What stage does Delos Capital invest at?
- Delos Capital invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does Delos Capital focus on?
- Delos Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is Delos Capital located?
- Delos Capital is headquartered in Cambridge, US.
- Who does Delos Capital co-invest with?
- Delos Capital most often shares deals with Ascension Ventures, New Enterprise Associates (NEA), Longitude Capital, among 63 tracked co-investors.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.